TheraVasc, Inc., a biotechnology company, develops repurposed drugs for vascular disease markets. It offers TV1001, an oral formulation of sodium nitrite that targets patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems, and peripheral artery disease. The company was incorporated in 2009 and